Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial.
暂无分享,去创建一个
William Berry | Oliver Sartor | J Alfred Witjes | Martine George | Mojtaba Noursalehi | J. Witjes | M. Wirth | C. Sternberg | N. James | D. Petrylak | O. Sartor | F. Calabrò | I. Bodrogi | M. Rozencweig | J. Ferrero | W. Berry | Tomasz Demkow | Manfred Wirth | S. Falcón | Jean-Marc Ferrero | Cora N Sternberg | P. Harper | T. McKearn | Daniel P Petrylak | Silvia Falcon | Jean-Christophe Eymard | Fabio Calabrò | Nicholas James | Istvan Bodrogi | Peter Harper | Michael E Petrone | Thomas J McKearn | Marcel Rozencweig | J. Eymard | M. George | D. Petrylak | T. Demkow | M. Petrone | M. Noursalehi | T. Mckearn | Poland Centre | Antoine Lacassagne | Sternberg
[1] M. Stockler,et al. Weekly docetaxel as second line treatment after mitozantrone for androgen‐independent prostate cancer , 2005, Internal medicine journal.
[2] M. Christian,et al. [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.
[3] R. Melzack. The McGill Pain Questionnaire: Major properties and scoring methods , 1975, PAIN.
[4] J. Forbes,et al. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] P. O'Brien,et al. A multiple testing procedure for clinical trials. , 1979, Biometrics.
[6] C. Tangen,et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.
[7] W. D. Ray. 4. Modelling Survival Data in Medical Research , 1995 .
[8] R. Maller,et al. Survival Analysis with Long-Term Survivors , 1996 .
[9] Susan Halabi,et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] E. Crawford,et al. Epidemiology of prostate cancer. , 2003, Urology.
[11] B. Freidlin,et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] C. Graham,et al. Use of the McGill Pain Questionaire in the assessment of cancer pain: Replicability and consistency , 1980, PAIN.
[13] A. Tamhane,et al. Multiple Comparison Procedures , 2009 .
[14] L. Kèlland,et al. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug. , 1993, Cancer research.
[15] L. Kèlland,et al. DNA‐binding properties of novel cis‐ and trans platinum‐based anticancer agents in 2 human ovarian carcinoma cell lines , 1995, International journal of cancer.
[16] J. Manola,et al. Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes. , 2006, Urology.
[17] C. Sternberg. Satraplatin in the treatment of hormone‐refractory prostate cancer , 2005, BJU international.
[18] F. Saad,et al. Canadian Urologic Oncology Group (CUOG) phase II multi-center study using docetaxel/prednisone in the second line setting for metastatic hormone-refractory prostate cancer in patients progressing after first line mitoxantrone/prednisone , 2005 .
[19] A. MacDonald. Modelling Survival Data in Medical Research. By D. Collett (Chapman & Hall, 1994) £19.99 , 1995, British Actuarial Journal.
[20] A. Tamhane,et al. Multiple Comparison Procedures , 1989 .
[21] V. Nelen. Epidemiology of prostate cancer. , 2007, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[22] D. Osoba,et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] C. Sternberg. Systemic chemotherapy and new experimental approaches in the treatment of metastatic prostate cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] Katherine S Panageas,et al. When you look matters: the effect of assessment schedule on progression-free survival. , 2007, Journal of the National Cancer Institute.
[25] I. Tannock,et al. Management of advanced prostate cancer after first-line chemotherapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] David C. Smith,et al. Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC) , 2004, Investigational New Drugs.
[27] G. Samimi,et al. Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters , 2006, Cancer Chemotherapy and Pharmacology.
[28] I. Tannock,et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.
[29] L. Collette,et al. Phase III Trial of Satraplatin, an Oral Platinum plus Prednisone vs. Prednisone alone in Patients with Hormone-Refractory Prostate Cancer , 2005, Oncology.
[30] I. Tannock,et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] L. Kèlland,et al. Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin. , 1992, Cancer research.
[32] R. Gray. A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .
[33] C. Sternberg. What's new in the treatment of advanced prostate cancer? , 2003, European journal of cancer.